Active Recombinant Human EGFL7 protein(Tyr24-Ser273), His-tagged
Cat.No. : | EGFL7-3077H |
Product Overview : | Recombinant Human EGFL7 (NP_057299.1) (Tyr 24-Ser 273) was expressed in Insect Cells, fused with a polyhistidine tag at the N-terminus. |
Availability | October 24, 2024 |
Unit | |
Price | |
Qty |
- Specification
- Gene Information
- Related Products
- Download
Source : | Insect Cells |
Species : | Human |
Tag : | His |
Protein length : | Tyr24-Ser273 |
Form : | Lyophilized from sterile 100mM Glycine, 10mM NaCl, 10% glycerol, pH 7.0. Normally 5 % - 8 % trehalose, mannitol and 0.01% Tween80 are added as protectants before lyophilization. |
Bio-activity : | 1. Measured by the ability of the immobilized protein to support the adhesion of NIH-3T3 mouse embryonic fibroblast cells. When 5 × 10E4 cells/well areadded to EGFL7-His coated plates (1.25μg/mL and 100μL/well),approximately >45% will adhere specifically after 30 minutes at 37°C. |
Molecular Mass : | The recombinant human EGFL7 consists of 268 amino acids and predicts a molecular mass of 29.4 kDa. It migRates as an approximately 31 kDa band in SDS-PAGE under reducing conditions. |
Endotoxin : | < 1.0 EU per μg of the protein as determined by the LAL method |
Purity : | > 85 % as determined by SDS-PAGE |
Storage : | Samples are stable for up to twelve months from date of receipt at -20°C to -80°C. Store it under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution of 0.2 ug/ul. Centrifuge the vial at 4°C before opening to recover the entire contents. |
Gene Name : | EGFL7 EGF-like-domain, multiple 7 [ Homo sapiens ] |
Official Symbol : | EGFL7 |
Synonyms : | EGFL7; EGF-like-domain, multiple 7; epidermal growth factor-like protein 7; ZNEU1; EGF-like protein 7; NOTCH4-like protein; vascular endothelial statin; multiple EGF-like domains protein 7; multiple epidermal growth factor-like domains protein 7; NEU1; VE-STATIN; RP11-251M1.2; MGC111117; |
Gene ID : | 51162 |
mRNA Refseq : | NM_016215 |
Protein Refseq : | NP_057299 |
MIM : | 608582 |
UniProt ID : | Q9UHF1 |
Products Types
◆ Recombinant Protein | ||
Egfl7-2759M | Recombinant Mouse Egfl7 Protein, Myc/DDK-tagged | +Inquiry |
EGFL7-1375H | Recombinant Human EGFL7 Protein, MYC/DDK-tagged | +Inquiry |
EGFL7-809H | Recombinant Human EGFL7 Protein, His (Fc)-Avi-tagged | +Inquiry |
EGFL7-3115H | Recombinant Human EGFL7 Protein, GST-tagged | +Inquiry |
EGFL7-1684R | Recombinant Rat EGFL7 Protein, His (Fc)-Avi-tagged | +Inquiry |
◆ Lysates | ||
EGFL7-649HCL | Recombinant Human EGFL7 cell lysate | +Inquiry |
EGFL7-565MCL | Recombinant Mouse EGFL7 cell lysate | +Inquiry |
Related Gene
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Inquiry
- Reviews
- Q&As
Customer Reviews (3)
Write a reviewThese resources can enhance the efficiency and accuracy of experimental workflows and contribute to successful outcomes.
Their collaboration, expertise, and customized solutions contribute to the successful execution of experiments, reliable data generation, and the advancement of scientific knowledge in the field.
The manufacturer's support is crucial for researchers using EGFL7 protein in trials.
Q&As (5)
Ask a questionTherapeutic interventions may involve targeting EGFL7 to modulate angiogenesis. This could be achieved through the development of drugs or therapies that either inhibit or enhance EGFL7 activity, depending on the clinical context.
EGFL7 interacts with various proteins involved in the angiogenic pathway, including growth factors and receptors. Understanding these interactions is essential for deciphering its role in angiogenesis.
Some research suggests that EGFL7 expression levels may have prognostic value in predicting outcomes for cancer patients. Higher or lower expression levels could be indicative of disease severity or response to treatment.
The regulation of EGFL7 expression is complex and varies in different conditions. Understanding the regulatory mechanisms is crucial for developing targeted therapies that modulate EGFL7 expression appropriately.
As of now, there are no widely accepted therapies specifically targeting EGFL7. However, ongoing research may lead to the development of targeted therapies in the future.
Ask a Question for All EGFL7 Products
Required fields are marked with *
My Review for All EGFL7 Products
Required fields are marked with *
Inquiry Basket